Pfizer Inc. (PFE)

25,69 -0,22 (-0,85 %) À la clôture : 04:00PM EDT

Pfizer Inc.

66 Hudson Boulevard East
New York, NY 10001-2192
United States
212 733 2323
https://www.pfizer.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 88 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Albert Bourla D.V.M., Ph.D.	Chairman of the Board & CEO	4,05M	S.O.	1962
Mr. David M. Denton	Chief Financial Officer & Executive VP	1,75M	S.O.	1965
Dr. Mikael Dolsten M.D., Ph.D.	Chief Scientific Officer and President of Research & Development	2,41M	S.O.	1958
Mr. Douglas M. Lankler	Executive VP & General Counsel	1,76M	S.O.	1966
Mr. Aamir Malik	Executive VP & Chief U.S. Commercial Officer	1,89M	S.O.	1976
Ms. Jennifer B. Damico	Senior VP, Controller & Principal Accounting Officer	S.O.	S.O.	1968
Ms. Lidia L. Fonseca	Executive VP and Chief Digital & Technology Officer	S.O.	S.O.	1969
Ms. Francesca M. DeMartino	Chief Investor Relations Officer	S.O.	S.O.	S.O.
Mr. Rady A. Johnson	Executive VP and Chief Compliance, Quality & Risk Officer	S.O.	S.O.	1962
Mr. Andreas J. Panayiotou	Global Chief Marketing Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Pfizer Inc. en date du 1 avril 2024 est 5. Les scores principaux sont Audit : 10; Société : 6; Droits des actionnaires : 1; Compensation : 3.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.